Evolving Role of CAR T Cell Therapy in First- and Second-Line Treatment of Large B Cell Lymphoma.
Anath C LionelJason R WestinPublished in: Current oncology reports (2023)
ZUMA-7 found significantly improved overall survival and event-free survival (EFS) with axicabtagene ciloleucel (axi-cel) versus SOC of salvage chemotherapy followed by autologous stem-cell transplantation. This represents the first such survival improvement in nearly 30 years for early-relapsed or refractory (r/r) LBCL. TRANSFORM demonstrated prolonged EFS for lisocabtagene maraleucel (liso-cel) versus SOC but BELINDA did not for tisagenlecleucel. Second-line CAR T cell was a viable curative-intent therapy in elderly (ZUMA-7; axi-cel) and/or transplant-ineligible (PILOT; liso-cel) patients. ZUMA-12 demonstrated effectiveness for axi-cel as part of first-line treatment for high-risk LBCL. These results support a role for CAR T cell therapy as new second-line SOC for r/r LBCL and highlight its potential evolution into future first-line treatment for high-risk disease.
Keyphrases
- cell therapy
- free survival
- stem cell transplantation
- stem cells
- mesenchymal stem cells
- end stage renal disease
- high dose
- diffuse large b cell lymphoma
- prognostic factors
- chronic kidney disease
- newly diagnosed
- ejection fraction
- randomized controlled trial
- systematic review
- acute lymphoblastic leukemia
- acute myeloid leukemia
- peritoneal dialysis
- middle aged
- multiple myeloma
- rectal cancer
- radiation therapy
- locally advanced
- chemotherapy induced